Island Pharmaceuticals (ASX: ILA) is significantly bolstering its US biodefence capabilities and engagement, announcing the appointment of a senior biodefence advisor and joining key industry working groups to advance its Marburg Virus Disease candidate, Galidesivir.
Island has appointed Mark Herzog as its Senior Global Health Security Advisor.
Mr Herzog brings a wealth of experience, with over 25 years in biodefence, government contracting, and medical countermeasure initiatives.
His track record includes securing more than US$100 million in government contracts.
His role is designed to enhance the company's engagement with US biodefence and global health security stakeholders.
Expanded Agency and Coalition Engagement
The company has also deepened its ties within the biodefence ecosystem, securing representation in two key working groups of the Medical Countermeasures Coalition (MC2).
These are the Research & Development and the Procurement & Stockpiling working groups.
The MC2 Research & Development group focuses on biodefence funding frameworks, platform technologies, and crucial regulatory pathways such as the FDA Animal Rule.
Meanwhile, the MC2 Procurement & Stockpiling group addresses Strategic National Stockpile (SNS) funding, inventory management, and "virtual stockpile" procurement frameworks.
Galidesivir Clinical Development Progress
Island Pharmaceuticals is making solid progress on the clinical development front for Galidesivir, its treatment candidate for Marburg Virus Disease.
The company is currently in advanced negotiations with US BSL-4 biocontainment facilities to finalise arrangements for Galidesivir's planned two-stage Animal Rule development.
Island is on track to commence a 30-day dose optimisation study next quarter.
This will be followed by pharmacokinetic (PK) analyses and a pivotal confirmatory efficacy study.
Building on Prior Milestones
In March 2026, Island Pharmaceuticals entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation.
This three-year agreement aims to accelerate Galidesivir development under the FDA Animal Rule.
Further strengthening its antiviral pipeline, Island Pharmaceuticals announced a strategic collaboration with Burnet Institute in March 2026 to evaluate ISLA-101 and Galidesivir against other viral threats including measles, chikungunya, and Ross River virus, leveraging an NHMRC grant of over A$780,000.
The company also secured a master service agreement with Texas Biomedical Research Institute in December 2025 to support non-human primate studies for Galidesivir.
In November 2025, Island gained membership into the US-based Medical Countermeasures Coalition.
Earlier in February 2026, Island Pharmaceuticals raised $9 million in a placement following positive FDA feedback that de-risked the Galidesivir Animal Rule pathway, providing capital to fund the next stages of development.
